Skip to content

ARCUTIS BIOTHERAPEUTICS, INC.

ARQT

CIK 0001787306

← back to feed
Revenue (TTM)
$351.97M
+91.3% YoY Q1 Apr 2026
Net Income (TTM)
−$44.83M
+88.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.36
+88.8% YoY Q1 Apr 2026
Gross Margin
90.1%
Q1 Apr 2026
Operating Margin
-11.3%
Q1 Apr 2026
Net Margin
-12.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$140.78M
Q1 Apr 2026
Cash
$34.76M
Q1 Apr 2026
Total Debt
$109.42M
Q1 Apr 2026
Shares Outstanding
125.08M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings